EGFR and Parkinson disease: The overexpression of pathological LRRK2 in LRRK2-mutant cells and fibroblasts from G2019S-LRRK2 PD patients decreases Rab7 activity and results in delayed endosomal trafficking and impaired epidermal growth factor receptor (EGFR) degradation, which can be reversed upon LRRK2 inhibition and overexpression of Rab7 [124].